Background Dysfunctional endothelium may contribute to the development of cardiovascular complications in
chronic kidney disease ( CKD ). Supplementation with active
vitamin D has been proposed to have vasoprotective potential in CKD , not only by direct effects on the endothelium but also by an increment of α-Klotho. Here, we explored the capacity of the active
vitamin D analogue
paricalcitol to protect against
uremia-induced endothelial damage and the extent to which this was dependent on increased α-Klotho concentrations. Methods and Results In a combined rat model of CKD with
vitamin D deficiency,
renal failure induced vascular permeability and endothelial-gap formation in thoracic aorta irrespective of baseline
vitamin D, and this was attenuated by
paricalcitol. Downregulation of renal and serum α-Klotho was found in the CKD model, which was not restored by
paricalcitol. By measuring the real-time changes of the human endothelial barrier function, we found that
paricalcitol effectively improved the recovery of endothelial integrity following the addition of the pro-permeability factor
thrombin and the induction of a
wound. Furthermore, immunofluorescence staining revealed that
paricalcitol promoted
vascular endothelial-cadherin-based cell-cell junctions and diminished
F-actin stress fiber organization, preventing the formation of endothelial intracellular gaps. Conclusions Our results demonstrate that
paricalcitol attenuates the CKD -induced endothelial damage in the thoracic aorta and directly mediates endothelial stability in vitro by enforcing cell-cell interactions.